You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

CLINICAL TRIALS PROFILE FOR PEMIGATINIB

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Pemigatinib

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02393248 ↗	Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Recruiting	Incyte Corporation	Phase 1/Phase 2	2015-02-27	The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
NCT02872714 ↗	A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)	Active, not recruiting	Incyte Corporation	Phase 2	2017-01-12	The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
NCT02924376 ↗	Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)	Completed	Incyte Corporation	Phase 2	2017-01-16	The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Pemigatinib

Condition Name

Chart
Table

Condition Name for Pemigatinib
Intervention	Trials
Breast Cancer	3
Gastrointestinal Cancer	3
Urothelial Carcinoma	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Pemigatinib
Intervention	Trials
Neoplasms	7
Cholangiocarcinoma	6
Carcinoma	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Pemigatinib

Trials by Country

Map
Table

Trials by Country for Pemigatinib
Location	Trials
United States	187
Italy	19
Japan	16
France	16
United Kingdom	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Pemigatinib
Location	Trials
Texas	10
Arizona	9
North Carolina	8
Georgia	8
Florida	8
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Pemigatinib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Pemigatinib
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	25
Phase 1/Phase 2	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Pemigatinib
Clinical Trial Phase	Trials
Recruiting	18
Not yet recruiting	6
Active, not recruiting	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pemigatinib

Sponsor Name

Chart
Table

Sponsor Name for Pemigatinib
Sponsor	Trials
Incyte Corporation	17
National Cancer Institute (NCI)	2
Academic and Community Cancer Research United	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Pemigatinib
Sponsor	Trials
Industry	23
Other	22
NIH	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.